Windward Bio is a clinical-stage drug development company focused on advancing treatments for severe immunological diseases, particularly severe respiratory conditions. The company is developing WIN378, a novel, fully human monoclonal antibody that targets thymic stromal lymphopoietin (TSLP), a cytokine implicated in various immunological disorders such as asthma and chronic obstructive pulmonary disease (COPD). WIN378 has been engineered for an extended half-life and effector silencing, allowing for subcutaneous administration, which enhances its therapeutic potential by effectively inhibiting the TSLP ligand and addressing multiple inflammatory phenotypes associated with these diseases.

In addition to WIN378, Windward Bio is also working on innovative bispecific antibody programs aimed at treating immunological diseases. These bispecific antibodies are designed to engage multiple targets simultaneously, potentially leading to improved efficacy and safety profiles in treating complex conditions. The company's commitment to advancing these cutting-edge therapies is supported by a highly experienced management team with extensive backgrounds in biopharmaceutical research, development, and commercialization, positioning Windward Bio as a promising player in the field of immunotherapy.

Switzerland

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.

Windward Bio

Company Details